Who are RGN-259's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, ASC, Cord blood, hUCB, Concentrated Bone Marrow Aspirate Injection, Stempeucel®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rgn-259.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

RGN-259 — Competitive Intelligence Brief

RGN-259 (RGN-259) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: stem cell therapy. Area: Ophthalmology.

phase 3 stem cell therapy Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

RGN-259 (RGN-259) — ReGenTree, LLC. RGN-259 is a stem cell therapy that aims to promote retinal regeneration.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RGN-259 TARGET	RGN-259	ReGenTree, LLC	phase 3	stem cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
ASC	ASC	Anterogen Co., Ltd.	marketed	Autologous stem cell therapy
Cord blood	Cord blood	New York Medical College	marketed	Hematopoietic stem cell therapy
hUCB	hUCB	StemCyte Taiwan Co., Ltd.	marketed	Allogeneic hematopoietic stem cell therapy
Concentrated Bone Marrow Aspirate Injection	Concentrated Bone Marrow Aspirate Injection	Hospital for Special Surgery, New York	marketed	Autologous stem cell therapy
Stempeucel®	Stempeucel®	Cell Biopeutics Resources Sdn Bhd	marketed	Allogeneic mesenchymal stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (stem cell therapy class)

ReGenTree, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RGN-259 — Competitive Intelligence Brief. https://druglandscape.com/ci/rgn-259. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab